Biomedicine and Pharmacotherapy Submission Guide

Source: Clarivate JCR 2024, Elsevier editorial disclosures (accessed April 2026).

Source: Biomedicine and Pharmacotherapy author guidelines.

Use this page when deciding:

• whether the pharmacotherapy contribution is substantive
• whether mechanism of action is articulated
• whether in-vivo validation is rigorous

• a clear pharmacotherapy contribution
• mechanism of action evidence
• in-vivo validation
• translational relevance
• a cover letter establishing the contribution

• Descriptive activity reports without mechanism.
• Weak in-vivo validation.
• Missing clinical relevance.
• Pure chemistry without pharmacotherapy focus.

Biomedicine and Pharmacotherapy is a flagship pharmacotherapy research journal.

Mechanism + translational standard: the journal differentiates from Pharmacological Research (broader) and Phytomedicine (natural-product focused) by demanding pharmacotherapy with mechanism and translational support.

In-vivo expectation: editors expect animal models or comparable validation.

The 30-40% desk rejection rate: decisive editorial screen.

The strongest Biomedicine and Pharmacotherapy cover letters establish:

• the pharmacotherapy contribution
• the mechanism of action
• the in-vivo validation
• the translational relevance

• Is Biomedicine and Pharmacotherapy a good journal?

Before upload, run your manuscript through a Biomedicine and Pharmacotherapy mechanism check.

In our pre-submission review work with biomedical manuscripts targeting Biomedicine and Pharmacotherapy, three patterns generate the most consistent desk rejections.

In our experience, roughly 35% of Biomedicine and Pharmacotherapy desk rejections trace to descriptive activity reports. In our experience, roughly 25% involve weak in-vivo validation. In our experience, roughly 20% arise from missing clinical relevance.

• Descriptive activity reports without mechanism. Biomedicine and Pharmacotherapy editors look for mechanism of action. We observe submissions reporting only activity data without mechanistic experiments routinely desk-rejected.

• Weak in-vivo validation. Editors expect animal models or comparable evidence. We see manuscripts with only in-vitro data on systems with therapeutic claims routinely returned.

• Missing clinical relevance. Biomedicine and Pharmacotherapy specifically expects translational connection. We find papers framed as pure chemistry without therapeutic application routinely declined. A Biomedicine and Pharmacotherapy mechanism check can identify whether the package supports a submission.

Clarivate JCR 2024 bibliometric data places Biomedicine and Pharmacotherapy among top pharmacotherapy journals.

In pre-submission diagnostic work for top pharmacotherapy journals, we consistently see four signals that distinguish strong submissions from weak ones. First, the pharmacotherapy contribution must be mechanistic. Second, in-vivo validation should be included. Third, translational relevance should be direct. Fourth, mechanism of action should be supported.

The single most consistent feedback class we deliver in pre-submission diagnostics for Biomedicine and Pharmacotherapy is the descriptive-versus-mechanistic distinction. Biomedicine and Pharmacotherapy editors expect mechanism with translation. Submissions framed as "we tested compound X in setting Y" routinely receive "where is the mechanism?" feedback. We coach authors to lead with the mechanism question and frame the activity in service of mechanism. Papers framed as "we elucidated how compound X exerts therapeutic effect Y by mechanism Z, validated in vivo" receive better editorial traction.

Beyond the rubric checks, three pre-submission diagnostic patterns recur most often in the manuscripts we review for Biomedicine and Pharmacotherapy. First, manuscripts where the abstract reports activity without mechanism are flagged. Second, manuscripts where in-vivo data is reported only in supplementary materials are flagged. Third, manuscripts that lack engagement with Biomedicine and Pharmacotherapy's recent issues are at risk of being told the contribution doesn't fit.

The strongest manuscripts we coach distinguish themselves on three operational behaviors. First, they confine the cover letter to one page. Second, they include a one-sentence elevator pitch. Third, they identify the specific recent papers in the journal that this manuscript builds on.

Editorial triage at journals at this tier operates on limited time per manuscript. Editors typically scan abstract, introduction, methodology, and conclusions before deciding whether to invite reviewer engagement. We coach researchers to design abstract, introduction, and conclusions for fast assessment.

Beyond methodology and contribution, journals at this tier weight author-team authority within the specific subfield. Strong submissions reference the journal's recent papers explicitly in the introduction and discussion. We coach researchers to identify 3-5 recent journal papers that this manuscript builds on.